These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3653765)

  • 1. Phase II trial of vinblastine in previously treated patients with ovarian cancer: a Southwest Oncology Group Study.
    Surwit EA; Alberts DS; O'Toole RV; Graham V; Hannigan EV; Stephens RL; Boutselis JG
    Gynecol Oncol; 1987 Sep; 28(1):14-9. PubMed ID: 3653765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of vinblastine in previously treated patients with ovarian cancer: a Southwest Oncology Group Study.
    Surwit EA; Alberts DS; O'Toole RV; Graham V; Hannigan EV; Stephens RL; Boutselis JG
    Gynecol Oncol; 1987 Jun; 27(2):214-9. PubMed ID: 3570059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of vinblastine in advanced ovarian carcinoma. A Gynecologic Oncology Group study.
    Sutton GP; Blessing JA; Adelson MD; Hanjani P
    Invest New Drugs; 1990 Nov; 8(4):377-9. PubMed ID: 2084071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer.
    Gershenson DM; Burke TW; Morris M; Bast RC; Guaspari A; Hohneker J; Wharton JT
    Gynecol Oncol; 1998 Sep; 70(3):404-9. PubMed ID: 9790795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I-II trial of a 5-day continuous infusion of vinblastine sulfate.
    Zeffren J; Yagoda A; Kelsen D; Winn R
    Anticancer Res; 1984; 4(6):411-3. PubMed ID: 6517534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
    Hochster H; Plimack ER; Runowicz CD; Speyer J; Wallach RC; Sorich J; Mandeli J; Wadler S; Wright J; Muggia FM
    J Clin Oncol; 2004 Jan; 22(1):120-6. PubMed ID: 14701774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-day continuous-infusion vinblastine in the treatment of breast cancer.
    Fraschini G; Yap HY; Hortobagyi GN; Buzdar A; Blumenschein G
    Cancer; 1985 Jul; 56(2):225-9. PubMed ID: 4005794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study.
    Samuels BL; Hollis DR; Rosner GL; Trump DL; Shapiro CL; Vogelzang NJ; Schilsky RL
    Clin Cancer Res; 1997 Nov; 3(11):1977-84. PubMed ID: 9815587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of divided-dose vinblastine in advanced cancer patients.
    Giaccone G; Bagatella M; Donadio M; Calciati A
    Tumori; 1989 Jun; 75(3):248-51. PubMed ID: 2773077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of vinblastine in patients with advanced or recurrent endometrial carcinoma. A Southwest Oncology Group Study.
    Thigpen JT; Kronmal R; Vogel S; Hynes HE; Nahhas W; Belt RJ; Balcerzak SP; Epstein RB; Costanzi JJ
    Am J Clin Oncol; 1987 Oct; 10(5):429-31. PubMed ID: 3661494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of merbarone (NSC 336628) in the treatment of recurrent epithelial ovarian carcinoma. A Gynecologic Oncology Group Study.
    Look KY; Blessing JA; Adelson MD; Morris M; Bookman MA
    Am J Clin Oncol; 1996 Feb; 19(1):7-9. PubMed ID: 8554040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer.
    Burger RA; DiSaia PJ; Roberts JA; O'rourke M; Gershenson DM; Homesley HD; Lichtman SM; Barnes W; Moore DH; Monk BJ
    Gynecol Oncol; 1999 Feb; 72(2):148-53. PubMed ID: 10021293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
    Tummarello D; Graziano F; Isidori P; Santo A; Cetto G; Fedeli A; Rossi G; Cellerino R
    Cancer; 1996 Jun; 77(11):2251-7. PubMed ID: 8635092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of 5-day infusion of vinblastine in patients with advanced ovarian carcinoma.
    Shah MK; St Marie K; Catalano RB; Dierks K; Creech RH
    Cancer Treat Rep; 1985 Feb; 69(2):229-30. PubMed ID: 3882232
    [No Abstract]   [Full Text] [Related]  

  • 16. Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
    Bookman MA; Malmström H; Bolis G; Gordon A; Lissoni A; Krebs JB; Fields SZ
    J Clin Oncol; 1998 Oct; 16(10):3345-52. PubMed ID: 9779711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Navelbine in advanced ovarian epithelial cancer: a study of the French oncology centers.
    George MJ; Heron JF; Kerbrat P; Chauvergne J; Goupil A; Lebrun D; Guastalla JP; Namer M; Bugat R; Ayme Y
    Semin Oncol; 1989 Apr; 16(2 Suppl 4):30-2. PubMed ID: 2652318
    [No Abstract]   [Full Text] [Related]  

  • 19. Phase II trial of piperazinedione (NSC 135758) in the treatment of advanced or recurrent carcinoma of the ovary. A Gynecologic Oncology Group study.
    Thigpen JT; Blessing JA; Arseneau JC; Homesley HD
    Am J Clin Oncol; 1984 Jun; 7(3):261-3. PubMed ID: 6547268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study.
    Gallion HH; Liu PY; Alberts DE; O'Toole RV; O'Sullivan J; Mills G; Smith HO; Hynes HE
    Gynecol Oncol; 1992 Aug; 46(2):230-2. PubMed ID: 1500027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.